X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

FDA Rebukes Althera On Cholesterol Medication Assertions

Content Team by Content Team
14th June 2022
in Manufacturing, Middle East and South Asia, News
FDA Rebukes Althera On Cholesterol Medication Assertions

Althera Pharmaceuticals, a producer of cardiovascular drugs, is being investigated by the FDA for its cholesterol oral delivery medicine, Roszet. The FDA’s Office of Prescription Medication Promotion is watching the drug, which combines two common cholesterol therapies into one pill, for promotional statements about its efficacy and risk.

The FDA maintains, among other things, that the data cited by the Morristown, New Jersey-based company does not support these assertions. The FDA wrote in an undated letter that such violations are especially concerning from a public health point of view because the advertising communication creates a false picture concerning the protection and efficiency of Roszet, which is a drug with numerous serious and potentially fatal risks.

Roszet, which will be available in 2021, combines the statins rosuvastatin and ezetimibe, a cholesterol uptake inhibitor, into a one-two punch. The pill has been authorised for adults to treat increased low-density lipoprotein cholesterol (LDL-C) in adults with basic non-familial hyperlipidemia and homozygous familial hypercholesterolemia, either alone or in combination with other LDL-C-reducing medications.

While statins are the primary line of treatment for lowering blood cholesterol, research has shown that combining statins with absorption inhibitors has substantial advantages. What is the significance of this? Roszet’s claims on this point, according to the federal watchdog, are false, not least since the research was not conducted by Roszet.

The FDA scoffs at Althera’s assertions of LDL-C reductions at specific doses: 59% at 5 mg, 64% at 10 mg, 66% at 20 mg, and up to 72% at 40 mg, as the brand boasts on its consumer splash page, and the company’s claims of “total” LDL-C reductions are not based on any Roszet studies. Rather, the technique utilised to create these percentages incorporates the results of two separate and incompatible research projects, the government claims. In patients with early hyperlipidemia, coronary heart disease, or several cardiac risk factors who had not accomplished their target LDL-C targets, one study looks at rosuvastatin alone, while the other considers the advantages of ezetimibe coupled to continued statin medication.

The business effectively sliced and diced the figures by merging the results of the two studies, neither of which examined Roszet’s combination of rosuvastatin and ezetimibe, contemplating that the research findings vary in patient population, statin type and dose, and test duration. While the FDA claims that the research Roszet cites supports the agency’s finding of safety and efficacy for the drug’s labelled indication of lowering LDL-C in certain patients, the studies’ multiple limitations negate their value in supporting any broad claims about the drug’s assisting patients in achieving specific LDL-C levels.

The FDA also singles out one example of what it terms false statements about a certain level of LDL-C (70 mg/dl) that patients can reach with just one pill per day, according to Roszet material. The issue, according to the FDA, is that the statement is based on studies in which the sub-70 mg/dl level was just a second outcome, and one of several in the research.

The FDA warned that as the number of endpoints assessed in a single research grows, the risk of drawing incorrect conclusions regarding the effect of the drug with regard to one or more of these endpoints can become a concern if proper multiplicity adjustment is not made. Althera now has two weeks to respond to the letter, and it may need to adjust its drug promotion strategy. Ezetimibe/Atorvastatin tablets (AL-310), the company’s second medication, has received FDA approval in both the United States and Europe and is scheduled to be available to patients next year.

The FDA has only issued three untitled letters this year, the other two being for Eli Lilly’s promotion of the diabetes drug Trulicity and Bausch’s skin treatment Duobrii.

Previous Post

Seqirus, North Carolina Gets Fill Finish Expansion of $156mn

Next Post

FDA Not So Fast On Approval Of The Novavax COVID-19 Vaccine

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

FDA Not So Fast On Approval Of The Novavax COVID-19 Vaccine

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In